期刊文献+

1,4-二氯酞嗪合成工艺研究 被引量:1

Study on synthesis of 1,4-dichlorophthalazine
下载PDF
导出
摘要 目的:优化1,4-二氯酞嗪的合成工艺,提高反应收率。方法:以邻苯二甲酸酐为原料,经缩合和氯代反应合成目标化合物。结果:改进了合成工艺,总收率提高到85.0%。合成的化合物结构均经HRMS和1H-NMR确证。结论:改进后的合成工艺,操作简化,产品质量提高,成本降低,该工艺切实可行,适合工业化生产。 Objective: To optimize synthetic process of 1,4-dichlorophthalazine and to increase the yield.Methods: The target compound was synthesized from phthalic anhydride by condensation and chlorination reaction.Results: The synthetic process was improved,and the overall yield was increased to 85.0%.The structure of the synthetic compound was identified by HRMS and 1H-NMR.Conclusion: After the improvement synthesis process,the operation is simplified,the product quality is enhanced and the cost is decreased,the improvement synthesis process is feasible and practicable to the industrialization production.
机构地区 郑州大学药学院
出处 《中国医药导报》 CAS 2011年第29期55-56,共2页 China Medical Herald
基金 郑州大学大学生创新性实验计划项目基金资助(项目编号:101045903)
关键词 1 4-二氯酞嗪 合成 缩合反应 氯代反应 1 4-dichlorophthalazine Synthesis Condensation Chlorination
  • 相关文献

参考文献8

二级参考文献61

  • 1D+CreativeTeam,Non-Format.无格式设计观[J].科技资讯,2005,3(21):46-52. 被引量:9
  • 2王占平,胡方中,邹小毛,杨秀凤,杨华铮.3-芳氧基-6-氯(或氟)哒嗪类化合物的合成及除草活性研究[J].农药学学报,2004,6(2):15-19. 被引量:10
  • 3MENDELSOHN J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy [ J ]. Clin Cancer Res, 1997,3(12) : 2703 -2707. 被引量:1
  • 4WILHELM SM, CARTER C, TANQ L. BAY 43-9006 exhibits broad spectrum oral antiumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases vinolved in tumor progression and angiogenesis [ J]. Cancer Res, 2004, 64 ( 19 ) : 7099 - 7109. 被引量:1
  • 5KUMAR R, ANGEL IS, CZENE K, et al. BRAF mutations in metastatic melanoma:a possible association with clinical outcome [J]. Clin Cancer Res, 2003, 9(9): 3362 -3368. 被引量:1
  • 6LE COUTRE P, OTTMANN OG, GILES F. Nilotinib (formerly AMNI07), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia [ J ]. Blood,2008, 111(4) :1834 - 1839. 被引量:1
  • 7MORGAN JA, DEMETR IGD, FLETCHER JA, et al. Patients with imatinib mesylate-resistant GIST exhibit durable responses to sunitinib malate ( SUl1248 ) [ J]. Eur J Cancer, 2005, 3 ( Suppl 2) : S.421. 被引量:1
  • 8PATYNA S, LAIRD AD, MENDEL DB, et al. SU14813:a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity [ J]. Mol Cancer Ther, 2006, 5 (7) : 1774 -1782. 被引量:1
  • 9IZZEDINE H, BUHAESCUL I, RIXE O, et al. Sunitinib malate [J]. Cancer Chemother Pharmacol, 2007, 60(3): 357 -364. 被引量:1
  • 10HERBST RS, HEYMACH JV, O'REILLY MS, et al. Vandetanib (ZD6474) : an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis [ J ]. Expert Opin lnvestig Drugs, 2007, 16 ( 2 ) : 239 - 249. 被引量:1

共引文献17

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部